EP3132270A1 - Verfahren zur diagnose von tuberkulöser meningitis - Google Patents

Verfahren zur diagnose von tuberkulöser meningitis

Info

Publication number
EP3132270A1
EP3132270A1 EP15779954.5A EP15779954A EP3132270A1 EP 3132270 A1 EP3132270 A1 EP 3132270A1 EP 15779954 A EP15779954 A EP 15779954A EP 3132270 A1 EP3132270 A1 EP 3132270A1
Authority
EP
European Patent Office
Prior art keywords
biomarkers
tbm
sample
meningitis
vegf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP15779954.5A
Other languages
English (en)
French (fr)
Other versions
EP3132270A4 (de
Inventor
Novel Njweipi Chegou
Gerhard Walzl
Anne Marceline VAN FURTH
Douwe Hendrik VISSER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stellenbosch University
Original Assignee
Stellenbosch University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stellenbosch University filed Critical Stellenbosch University
Publication of EP3132270A1 publication Critical patent/EP3132270A1/de
Publication of EP3132270A4 publication Critical patent/EP3132270A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/35—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Mycobacteriaceae (F)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4721—Cationic antimicrobial peptides, e.g. defensins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5437—IL-13

Definitions

  • the invention relates to a method for diagnosing tuberculous meningitis.
  • TBM TBM develops within a few months after the primary infection [3].
  • Outcome of TBM is often poor despite adequate anti-TB therapy, and early initiation of treatment is the most critical factor affecting morbidity, mortality and healthcare costs, which emphasizes the importance of early diagnosis of TBM [4].
  • the lack of sensitive methods for early TBM diagnosis is the most common cause for delayed diagnosis.
  • CSF cerebrospinal fluid
  • TBM Nucleic acid amplification techniques for the diagnosis of TBM are promising but still undergoing assessment in the pediatric population and are not yet suitable for widespread use in resource-poor countries [4]. Many attempts have been made to develop simplified, mostly antigen-detection, tests for TB but their diagnostic power remains poor. Therefore, in clinical practice the diagnosis of TBM is most often based on a combination of clinical, laboratory and radiological findings.
  • TBM tuberculous meningitis
  • IL-13 lnterleukin-13
  • VEGF Vascular endothelial growth factor
  • LL-37 Cathelicidin
  • IL-17 IL-12p70
  • IFN- ⁇ IFN- ⁇
  • IL-6 IL-6
  • IL-10 IL-13
  • IP-10 MIP- 1 a, MIP-1 b, RANTES and GM-CSF in a sample from a subject suspected of having TBM
  • the method may provide a positive diagnosis for TBM when level of IL-13, VEGF, LL-37, IL-12p70, IFN-Y, IL-6, IL-10, IL-13, IP-10, MIP-1 a, MIP-1 b and/or RANTES in the sample is higher than typical levels of the same biomarker(s) in subjects without tuberculous meningitis, and more specifically is higher than typical levels of the same biomarker(s) in subjects with viral meningitis or bacterial meningitis.
  • a positive diagnosis for TBM may be made when the level of IL-17 and/or GM-CSF in the sample is lower than a typical level of the same biomarker in subjects without tuberculous meningitis, and more particularly is lower than typical levels of the same biomarker(s) in subjects with viral meningitis or bacterial meningitis.
  • the levels of at least three of the biomarkers listed above may be measured in the sample.
  • the at least two or three biomarkers may be selected from the group consisting of IL-13, VEGF, LL-37 and IL-17, and more preferably from the group consisting of IL-13, VEGF and LL-37.
  • the sample may be of cerebrospinal fluid or serum from the patient.
  • a capture agent and indicator may be used to bind to each of the biomarkers, and an indicator may be provided to indicate when binding of the capture agents and biomarkers occurs.
  • the capture agents may be antibodies, affybodies, ankyrin repeat proteins, armadillo repeat proteins, nucleic acid aptamers, modified nucleic acid aptamers, peptides, modified peptides, carbohydrate ligands, synthetic ligands, and synthetic polymers.
  • the indicator may be a calorimetric, electrochemical, chromogenic, optical, fluorescent or a radio-labeled indicator.
  • a device for diagnosing tuberculous meningitis comprising:
  • IL-13 lnterleukin-13
  • VEGF Vascular endothelial growth factor
  • At least one indicator which indicates when the capture agents bind to the biomarkers.
  • the capture agents and indicator may be as described above.
  • the device may include means for detecting binding of the capture agent to the biomarker, by, for example, electrical, acoustic, optical or mechanical methods.
  • the device may be a point-of-care device.
  • TBM tuberculous meningitis
  • the kit comprising: capture agents for binding at least two biomarkers selected from the group consisting of lnterleukin-13 (IL-13), Vascular endothelial growth factor (VEGF), Cathelicidin (LL-37), IL-17, IL-12p70, IFN- ⁇ , IL-6, IL-10, IL-13, IP-10, MIP-1 a, MIP-1 b, RANTES and GM-CSFif present in the sample; and
  • At least one indicator which indicates when the capture agents bind to the biomarkers.
  • the capture agents and indicator may be as described above.
  • the kit may include a device as described above.
  • the kit may also include instructions for performing the method of diagnosis described above.
  • FIG. 1 Flow diagram of study participants. a Clinical case definition of Marais et al. 7 b Of the 44 "no meningitis" cases, 20 patients were selected at random for analysis.
  • CSF cerebrospinal fluid
  • TBM tuberculous meningitis.
  • the normalized values for each biomarker are depicted according to the color scale, where red and green represent expression above and below the median, respectively.
  • the dendrogram left shows the proximity between the different biomarkers, suggesting that biomarkers within each sub-cluster probably share the same origin, common transcriptional regulation and/or common function.
  • Significant clustering of TBM cases is seen in CSF but not in serum.
  • FIG 3A Three-dimensional unsupervised hierarchical clustering analysis and principal component analysis (PCA) of biomarkers in CSF and serum of TBM and non-TBM cases. Each dot represents one subject based on values of all biomarkers studied. The percentage of variances is depicted on the 3 axes. The distance in space between each dot represents the relatedness between each individual. Visual clustering of TBM cases is seen in CSF but not in serum.
  • Figure 4 Biomarker expression profiles in CSF of TBM and subgroups of non-TBM cases.
  • FIG. 5 Top canonical pathways in TBM, bacterial meningitis and viral meningitis.
  • the top canonical pathways in tuberculous meningitis (TBM), bacterial meningitis, and viral meningitis are presented.
  • TBM tuberculous meningitis
  • bacterial meningitis bacterial meningitis
  • viral meningitis are presented.
  • the -log(p-value) indicates the likelihood of an association between a specific pathway and the dataset.
  • the threshold line represents a p-value of 0 05.
  • Pathways associated with IL-17 signalling, hypercytokinemia, and communication between immune cells are relevant to all three types of meningitis.
  • a method for diagnosing tuberculous meningitis is described herein.
  • a fluid sample from a subject suspected of having TBM is tested for the presence of at least two, at least three or at least four of the following biomarkers: lnterleukin-13 (IL-13), Vascular endothelial growth factor (VEGF), Cathelicidin (LL-37), IL-17, IL-12p70, IFN- ⁇ , IL-6, IL-10, IL-13, IP-10, MIP-1 a, MIP-1 b, RANTES and GM-CSF. If these biomarkers in the sample are found to be over- or under-expressed compared to levels in subjects without TBM, then this is indicative that the subject has TBM.
  • a positive diagnosis for TBM can be made when the level of IL-13, VEGF, LL-37, IL-12p70, IFN- ⁇ , IL-6, IL-10, IL-13, IP-10, MIP-1 a, MIP-1 b and/or RANTES in the sample is higher than a typical level of the same biomarker in subjects without tuberculous meningitis, and more specifically is higher than typical levels of the same biomarker(s) in subjects with viral meningitis or bacterial meningitis.
  • a positive diagnosis for TBM can be made when the level of IL-17 and/or GM- CSF in the sample is lower than a typical level of the same biomarker in subjects without tuberculous meningitis, and more specifically is lower than typical levels of the same biomarker(s) in subjects with viral meningitis or bacterial meningitis.
  • the sample may be of cerebrospinal fluid or serum from the subject.
  • the at least two, at least three or at least four biomarkers are selected from the group consisting of IL-13, VEGF, LL-37 and IL-17. In another embodiment the at least two or at least three biomarkers are selected from the group consisting of IL-13, VEGF and LL-37. In yet other embodiments, the at least two biomarkers are IL-13 and VEGF, IL-13 and LL-37, or VEGF and LL-37.
  • a capture agent and indicator can be used to bind to each of the biomarkers, and an indicator indicates when binding of the capture agents and each of the biomarkers occurs.
  • biomarkers can be detected using commercially available techniques, such as ELISA techniques or multiplex bead array technology, although it is intended that a specific point- of-care diagnostic device will be developed for performing the method, particularly for use in resource poor settings.
  • Cut-off or threshold values can be determined based on levels of biomarkers which are typically found in patients without tuberculous meningitis or in subjects with viral meningitis or bacterial meningitis, and the levels of the biomarkers detected in the sample can be compared to the cut-off levels when making the determination of whether or not the subject has TBM.
  • the method will detect whether the biomarkers in the panels are under- or over-expressed relative to a subject who does not have TBM or relative to a subject who has viral meningitis or bacterial meningitis.
  • Antibodies, affybodies, ankyrin repeat proteins, armadillo repeat proteins, nucleic acid aptamers, modified nucleic acid aptamers, peptides, modified peptides, carbohydrate ligands, synthetic ligands or synthetic polymers can be used as the capture agents, and the indicator can be a calorimetric, electrochemical, chromogenic, optical, fluorescent or a radio-labeled indicator.
  • the method can be used as an initial diagnostic tool whereby a positive diagnosis from this method can, if necessary, be subsequently confirmed by means of a second diagnostic method. In the interim, while waiting for the results of the second test, the subject can be started on treatment. Conversely, the method of the invention can also be used to rule out TBM, thus preventing overtreatment of non-TBM subjects.
  • the method of the invention can be performed using a diagnostic device which detects and indicates the presence of the biomarkers in the sample.
  • the device has a means for receiving the sample from the subject, such as a loading or receiving area onto or into which the sample is placed.
  • the capture agents and indicators are present in the device, and once the sample has been loaded onto or received into the device, the sample is brought into contact with the capture agents, which are allowed to bind to the biomarkers if present.
  • the indicator will signify that binding has occurred.
  • the device is typically a point-of-care device, such as a lateral flow device.
  • a hand-held device is in the process of being developed which is capable of making a TBM diagnosis based on a lateral flow assay using up-converting phosphor technology.
  • the device may be a dip-stick which can be dipped into the cerebrospinal fluid or serum sample or onto which the sample can be placed, similar to many home pregnancy test kits.
  • the capture agents are included on the dipstick, and generate a signal when they bind to the biomarkers in the panel, together with a control signal.
  • Cytomegalovirus (CMV), Human Herpes Virus-6 (HV-6), Epstein-Barr virus (EBV), Herpes Simplex Virus 1 (HSV-1 ), Herpes Simplex Virus 2 (HSV-2), and Varicella Zoster Virus (VZV)
  • Enterovirus and Mumps was performed in the National Health Laboratory Service of the Tygerberg Hospital when there was viral meningitis was suspected.
  • TBM was classified as "Definite” when acid-fast bacilli were evident in the CSF, M. tuberculosis was cultured from the CSF, or M. tuberculosis was detected by one of the two commercial nucleic-acid amplification tests in the CSF in a patient with symptoms or signs suggestive of the disease.
  • TBM was classified as "Probable” when patients had a diagnostic score ⁇ 12, when cerebral imaging was available, and ⁇ 10 when imaging was unavailable.
  • TBM was classified as "Possible” when a patient had a diagnostic score of 6- 1 1 when imaging was available and 6-9 when imaging was unavailable. Diagnostic scores were based on the uniform clinical case definition of Marais et al [7].
  • Non-TBM patients were classified as non-TBM when an alternative diagnosis was established.
  • the non-TBM group was subdivided into 3 groups: 1 ) viral meningitis cases; 2) bacterial meningitis cases; and 3) a heterogeneous group of no meningitis cases.
  • Viral meningitis All children with a PCR-confirmed diagnosis of viral meningitis as well as those who had a leucocyte count of ⁇ 10 x10 6 /l in the CSF in the absence of microorganisms on Gram stain or on routine culture and a clinical course consistent with viral meningitis were included in this group [18].
  • Bacterial meningitis All cases with a positive CSF culture, bacteria seen on Gram stain or a positive bacterial antigen latex agglutination tests. Furthermore cases with characteristic features of bacterial meningitis in the CSF (high protein, low glucose, polymorph predominance) with or without a positive blood culture for a bacterial pathogen and a clinical course consistent with bacterial meningitis were also included in this group.
  • the levels of host biomarkers in serum and CSF were measured by the Luminex multiplex bead array technology. Twenty-seven host markers including interleukin-1 beta ( I L-1 ⁇ ), IL- 1 receptor antagonist (IL-1 RA), IL- 2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12 (p70), IL- 13, IL-15, IL-17, Interferon gamma (IFN- ⁇ ), tumor necrosis factor alpha (TNF-a), macrophage inflammatory protein 1 alpha (MIP-1 a), macrophage inflammatory protein 1 beta (MIP-1 ⁇ ), granulocyte colony stimulating factor (G-CSF), granulocyte macrophage colony stimulating factor (GM-CSF), eotaxin, fibroblast growth factor basic (FGF-basic), monocyte chemotactic protein (MCP-1 ), regulated upon activation normal T-cell expressed and secreted (RANTES), IFN-y-
  • Biological pathway analysis was performed using Ingenuity Pathway Analysis (Ingenuity Systems, Inc., Redwood, CA), which resulted in identification of the top canonical pathways of the markers found in the three different meningitis categories.
  • Headache 22 (39.3) 33 (60.0) 0.43 (0.16 - 1 .17) 0.03
  • TBM tuberculous meningitis
  • HIV human immunodeficiency virus
  • SD Standard deviations
  • BMI body mass index
  • each of these 28 biomarkers are illustrated in Figure 2.
  • Statistically significantly elevated concentrations of IL-12p70, IFN- ⁇ , VEGF, LL-37, IL-6, IL-10, IL-13, IP-10, MIP-1 a, MIP-1 b and RANTES and lower concentrations of IL-17 and GM-CSF were observed in CSF of TBM patients as compared to the non-TBM group.
  • Unsupervised hierarchical clustering and principal component analysis in CSF and serum To evaluate the presence of a TBM-specific biomarker profile, unsupervised hierarchical 25 clustering (UHC) analysis and principal component analysis (PCA) were done. Significant clustering of TBM cases was seen in CSF samples but not in serum samples ( Figure 3a). The UHC results in CSF samples were confirmed by PCA ( Figure 3b). To highlight the disease-specific biomarker signature profile in CSF grouped medians of each type of meningitis (TBM, VM and BM) and the "no meningitis" group were calculated and UHC was repeated. Highly significant distinct biomarker profiles were found between the 4 subgroups ( Figure 4).
  • TBM-specific biomarker signature profile was found in CSF with UHC, PCA and pathway analysis, the value of a biomarker-based diagnostic model for TBM was evaluated. All TBM cases were used for this analysis. Biomarkers that were significantly different between the TBM group and the 2 other groups of meningitis (BM and VM) were entered in the multivariable logistic regression model. Spline analysis was done to evaluate linearity of the factors. As none of the selected biomarkers showed linearity and sample size was limited, variables were dichotomized with maximum Youden-index (Maximum ⁇ (Sensitivity + Specificity) -1 ⁇ ) used as cut-off values. Stepwise backward selection (p-value 0.10) based on the Wald test was used to identify variables.
  • the final diagnostic model consists of three biomarkers, IL-13, VEGF and LL-37.
  • a ROC curve based on the predicted probability of the model was calculated with an AUC of 0.929 (95%CI 0.877 - 0.981 ).
  • the AUC was 0.921 and regression coefficients were adjusted by a correction factor of 0.912.
  • Sensitivity, specificity, PPV and NPV of the three biomarkers individually and in combination are outlined in Table 3. Highest specificity is obtained when all biomarkers (IL-13, VEGF and LL-37) are found upregulated with a test sensitivity of 0.52, specificity of 0.95, PPV of 0.91 and NPV of 0.66.
  • WHO World Health Organization
  • Global Tuberculosis Control WHO report 201 1 . http://www.who.int/tb/publications/global_report/201 1 /gtbr1 1_main.pdf (April 15th 2012, date last accessed)
  • van der Flier M Stockhammer G, Vonk GJ, Nikkels PG, van Diemen-Steenvoorde RA, van der Vlist GJ, et al. Vascular endothelial growth factor in bacterial meningitis: detection in cerebrospinal fluid and localization in postmortem brain. The Journal of infectious diseases. 2001 Jan 1 ;183(1 ):149-53. PubMed PMID: 1 1 106541 .
  • Vitamin D3 induces autophagy in human monocytes/macrophages via cathelicidin. Cell host & microbe. 2009 Sep 17;6(3):231 - 43. PubMed PMID: 19748465.
EP15779954.5A 2014-04-15 2015-04-15 Verfahren zur diagnose von tuberkulöser meningitis Withdrawn EP3132270A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ZA201402743 2014-04-15
PCT/IB2015/052751 WO2015159239A1 (en) 2014-04-15 2015-04-15 A method for diagnosing tuberculous meningitis

Publications (2)

Publication Number Publication Date
EP3132270A1 true EP3132270A1 (de) 2017-02-22
EP3132270A4 EP3132270A4 (de) 2017-09-13

Family

ID=54323552

Family Applications (1)

Application Number Title Priority Date Filing Date
EP15779954.5A Withdrawn EP3132270A4 (de) 2014-04-15 2015-04-15 Verfahren zur diagnose von tuberkulöser meningitis

Country Status (5)

Country Link
EP (1) EP3132270A4 (de)
CN (1) CN106461674A (de)
AP (1) AP2016009538A0 (de)
RU (1) RU2016144359A (de)
WO (1) WO2015159239A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017178826A1 (en) * 2016-04-14 2017-10-19 The University Of Liverpool Diagnosing acute bacterial meningitis
CN107421875A (zh) * 2017-04-29 2017-12-01 济南市儿童医院 Mfsd2a在制备诊断化脓性脑膜炎制品中的应用
US20210199668A1 (en) * 2018-05-23 2021-07-01 Stellenbosch University Biomarkers for diagnosing tuberculous meningitis
CN112899340B (zh) * 2021-03-15 2022-09-27 首都医科大学附属北京胸科医院 一种辅助诊断结核性脑膜炎的试剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE479097T1 (de) * 2001-05-18 2010-09-15 Virogates Aps Verfahren zur diagnose oder prognostizierung der wesentlichen bakteriellen erreger von atemwegserkrankungen in einem patienten
SG150497A1 (en) * 2004-07-23 2009-03-30 Aspenbio Pharma Inc Methods and devices for diagnosis of appendicitis
AP2011005546A0 (en) * 2008-06-25 2011-02-28 Baylor Res Intitute Blood transcriptional signature of mycobacterium tuberculosis infection.
US20110129817A1 (en) * 2009-11-30 2011-06-02 Baylor Research Institute Blood transcriptional signature of active versus latent mycobacterium tuberculosis infection
WO2013175459A2 (en) * 2012-05-25 2013-11-28 Stellenbosch University Method for diagnosing tuberculosis disease

Also Published As

Publication number Publication date
AP2016009538A0 (en) 2016-11-30
WO2015159239A1 (en) 2015-10-22
WO2015159239A4 (en) 2015-12-17
CN106461674A (zh) 2017-02-22
RU2016144359A (ru) 2018-05-15
EP3132270A4 (de) 2017-09-13
RU2016144359A3 (de) 2018-05-15

Similar Documents

Publication Publication Date Title
US10001481B2 (en) Method for diagnosing tuberculosis disease by detecting induced markers after stimulation of T-cells with antigens
Jacobs et al. Identification of novel host biomarkers in plasma as candidates for the immunodiagnosis of tuberculosis disease and monitoring of tuberculosis treatment response
Chegou et al. Beyond the IFN-γ horizon: biomarkers for immunodiagnosis of infection with Mycobacterium tuberculosis
De-La-Torre et al. Severe South American ocular toxoplasmosis is associated with decreased Ifn-γ/Il-17a and increased Il-6/Il-13 intraocular levels
Manyelo et al. Tuberculous meningitis: pathogenesis, immune responses, diagnostic challenges, and the potential of biomarker-based approaches
Geluk et al. New biomarkers with relevance to leprosy diagnosis applicable in areas hyperendemic for leprosy
Abdallah et al. Neonatal levels of cytokines and risk of autism spectrum disorders: an exploratory register-based historic birth cohort study utilizing the Danish Newborn Screening Biobank
Wu et al. Multiple cytokine responses in discriminating between active tuberculosis and latent tuberculosis infection
CN106537146B (zh) 生物标志
Clifford et al. Cytokine biomarkers for the diagnosis of tuberculosis infection and disease in adults in a low prevalence setting
Armand et al. Cytokine responses to quantiferon peptides in pediatric tuberculosis: a pilot study
Wang et al. Screening and identification of a six-cytokine biosignature for detecting TB infection and discriminating active from latent TB
Jayakumar et al. Serum biomarkers of treatment response within a randomized clinical trial for pulmonary tuberculosis
Walzl et al. Clinical immunology and multiplex biomarkers of human tuberculosis
Luo et al. Diagnostic performance of plasma cytokine biosignature combination and MCP-1 as individual biomarkers for differentiating stages Mycobacterium tuberculosis infection
EP3132270A1 (de) Verfahren zur diagnose von tuberkulöser meningitis
US20140342936A1 (en) Methods and kits for diagnosing latent tuberculosis infection
Yang et al. IP-10 and MIG are compartmentalized at the site of disease during pleural and meningeal tuberculosis and are decreased after antituberculosis treatment
Shiratori et al. Elevated OPN, IP-10, and neutrophilia in loop-mediated isothermal amplification confirmed tuberculosis patients
Wei et al. Regulation network of serum cytokines induced by tuberculosis-specific antigens reveals biomarkers for tuberculosis diagnosis
Chen et al. Cytokine and antibody based diagnostic algorithms for sputum culture-positive pulmonary tuberculosis
Eribo et al. Host urine immunological biomarkers as potential candidates for the diagnosis of tuberculosis
Kabeer et al. Comparison of interferon gamma–inducible protein-10 and interferon gamma–based QuantiFERON TB Gold assays with tuberculin skin test in HIV-infected subjects
Ravindran et al. Exploratory study on plasma immunomodulator and antibody profiles in tuberculosis patients
Shi et al. Use of DosR dormancy antigens from Mycobacterium tuberculosis for serodiagnosis of active and latent tuberculosis

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20161110

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20170814

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/68 20060101AFI20170808BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20180313